Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

EYE ON CHINA
AstraZeneca’s heart drug wins approval
A straZeneca’s new heart drug, Brilinta, has been approved by China’s State Food and Drug Administration, which has issued a drug import license for the product. This means Brilinta (ticagrelor ) will now be available for treating patients with acute coronary syndrome in China.

Brilinta has already been proved better than the cheaper generic version, Plavix (clopidogrel ), in preventing the recurrence of heart attacks in several studies. Plavix is marketed by Bristol-Myers Squibb and Sanofi.

While the drug sales have not been as good as originally hoped, China is an increasingly important market for AstraZeneca and this recent approval may help to improve sales.

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.